HDFC Mutual Fund and ADIA Join Forces as Sepia Investments Sells Rs 749 Crore Stake in Corona Remedies through Block Deal.
On June 17, 2026, a significant block deal took place involving Sepia Investments’ divestiture of shares in Corona Remedies Limited, amounting to approximately Rs 749 crore. Sepia Investments sold 43,28,943 shares at a price point of Rs 1,730 each, culminating in a transaction valued at roughly Rs 748.9 crore. Anchor Partners also participated in the sale, offloading 1,61,861 shares at the same price, contributing an additional Rs 28 crore to the total divestment. Collectively, these transactions represented a substantial divestment of approximately Rs 776.9 crore within the pharmaceutical sector.
The buy-side of this transaction saw considerable interest from prestigious institutional investors. Notably, HDFC Mutual Fund emerged as the key player, acquiring 24,50,000 shares worth about Rs 423.9 crore, which constituted over half of the total deal value. Other notable investors included the Aberdeen Asian Smaller Companies Investment Trust Plc, which secured 4,50,868 shares valued at roughly Rs 78 crore, and Aditya Birla Sun Life Mutual Fund, which purchased 4,90,000 shares costing around Rs 84.8 crore. The Abu Dhabi Investment Authority also entered the fray, acquiring 39,130 shares for about Rs 6.8 crore.
Several additional investors complemented this buyer pool, including Aberdeen Standard Sicav I – Asian Smaller Companies Fund and Invesco Mutual Fund, who made substantial purchases amounting to Rs 47.4 crore and Rs 50 crore, respectively. Kotak Mahindra Mutual Fund matched the exact quantity sold by Anchor Partners, acquiring 1,61,861 shares valued at around Rs 28 crore. The overall dynamics of this transaction illustrate robust confidence among institutional investors in the growth trajectory of Corona Remedies Limited, emphasizing its strategic importance within the pharmaceutical landscape.
This block deal reflects a notable shift in shareholder composition for Corona Remedies, as high-caliber institutional investors bolster their stakes amid an evolving pharmaceutical market. The prominence of renowned entities such as HDFC Mutual Fund and the Abu Dhabi Investment Authority signals a potential bullish outlook for the company, making this a pivotal moment for Wealthova investors to assess the implications of institutional sentiment on market performance and future valuations.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)